Prevalence and Influence Factors for Non-Alcoholic Fatty Liver Disease in Long-Term Hospitalized Patients with Schizophrenia: A Cross-Sectional Retrospective Study

References

• Singh T, Poterba T, Curtis D, et al. Rare coding variants in ten genes confer substantial risk for schizophrenia. Nature. 2022;604(7906):509–516. doi:10.1038/s41586-022-04556-w
   PubMed Web of Science ®Google Scholar
• Paquin V, Lapierre M, Veru F, King S. Early environmental upheaval and the risk for schizophrenia. Annu Rev Clin Psychol. 2021;17:285–311. doi:10.1146/annurev-clinpsy-081219-103805
   PubMed Web of Science ®Google Scholar
• Cloutier M, Aigbogun MS, Guerin A, et al. The economic burden of schizophrenia in the United States in 2013. J Clin Psychiatry. 2016;77(6):764–771. doi:10.4088/JCP.15m10278
   PubMed Web of Science ®Google Scholar
• McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia-an overview. JAMA Psychiatry. 2020;77(2):201–210. doi:10.1001/jamapsychiatry.2019.3360
   PubMed Web of Science ®Google Scholar
• Zhang R, Sjölander A, Ploner A, Lu D, Bulik CM, Bergen SE. Novel disease associations with schizophrenia genetic risk revealed in ~400,000 UK Biobank participants. Mol Psychiatry. 2022;27(3):1448–1454. doi:10.1038/s41380-021-01387-5
   PubMed Web of Science ®Google Scholar
• Yang C, Zhong X, Zhou H, Wu Z, Zhang M, Ning Y. Physical comorbidities are independently associated with higher rates of psychiatric readmission in a Chinese Han population. Neuropsychiatr Dis Treat. 2020;16:2073–2082. doi:10.2147/NDT.S261223
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357. doi:10.1002/hep.29367
   PubMed Web of Science ®Google Scholar
• Henry L, Paik J, Younossi ZM. Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world. Aliment Pharmacol Ther. 2022;56(6):942–956. doi:10.1111/apt.17158
   PubMed Web of Science ®Google Scholar
• Zhou F, Zhou J, Wang W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis. Hepatology. 2019;70(4):1119–1133. doi:10.1002/hep.30702
   PubMed Web of Science ®Google Scholar
• Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47–64. doi:10.1016/j.jhep.2014.12.012
   PubMed Web of Science ®Google Scholar
• Erlangsen A, Andersen PK, Toender A, Laursen TM, Nordentoft M, Canudas-Romo V. Cause-specific life-years lost in people with mental disorders: a nationwide, register-based cohort study. Lancet Psychiatry. 2017;4(12):937–945. doi:10.1016/S2215-0366(17)30429-7
   PubMed Web of Science ®Google Scholar
• Melo APS, Dippenaar IN, Johnson SC, et al. All-cause and cause-specific mortality among people with severe mental illness in Brazil’s public health system, 2000-2015: a retrospective study. Lancet Psychiatry. 2022;9(10):771–781. doi:10.1016/S2215-0366(22)00237-1
   PubMed Web of Science ®Google Scholar
• Räsänen S, Hakko H, Viilo K, et al. Excess mortality among long-stay psychiatric patients in Northern Finland. Soc Psychiatry Psychiatr Epidemiol. 2003;38(6):297–304. doi:10.1007/s00127-003-0635-2
   PubMed Web of Science ®Google Scholar
• Ringen PA, Faerden A, Antonsen B, et al. Cardiometabolic risk factors, physical activity and psychiatric status in patients in long-term psychiatric inpatient departments. Nord J Psychiatry. 2018;72(4):296–302. doi:10.1080/08039488.2018.1449012
   PubMed Web of Science ®Google Scholar
• Osimo EF, Sweeney M, de Marvao A, et al. Adipose tissue dysfunction, inflammation, and insulin resistance: alternative pathways to cardiac remodelling in schizophrenia. A multimodal, case-control study. Transl Psychiatry. 2021;11(1):614. doi:10.1038/s41398-021-01741-9
   PubMed Web of Science ®Google Scholar
• Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69(9):1691–1705. doi:10.1136/gutjnl-2020-320622
   PubMed Web of Science ®Google Scholar
• Ma Q, Yang F, Ma B, et al. Prevalence of nonalcoholic fatty liver disease in mental disorder inpatients in China: an observational study. Hepatol Int. 2021;15(1):127–136. doi:10.1007/s12072-020-10132-z
   PubMed Web of Science ®Google Scholar
• Koreki A, Mori H, Nozaki S, et al. Risk of Nonalcoholic Fatty Liver Disease in Patients With Schizophrenia Treated With Antipsychotic Drugs: a Cross-sectional Study. J Clin Psychopharmacol. 2021;41(4):474–477. doi:10.1097/JCP.0000000000001421
   PubMed Web of Science ®Google Scholar
• Yan J, Hou C, Liang Y. The prevalence and risk factors of young male schizophrenics with non-alcoholic fatty liver disease. Neuropsychiatr Dis Treat. 2017;13:1493–1498. doi:10.2147/NDT.S137183
   PubMed Web of Science ®Google Scholar
• Leucht S, Samara M, Heres S, Davis JM. Dose equivalents for antipsychotic drugs: the DDD method. Schizophr Bull. 2016;42(suppl 1):S90–S94. doi:10.1093/schbul/sbv167
   PubMedGoogle Scholar
• Wong VW, Chan WK, Chitturi S, et al. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33(1):70–85. doi:10.1111/jgh.13857
   PubMed Web of Science ®Google Scholar
• Hafkenscheid A. Psychometric evaluation of a standardized and expanded Brief Psychiatric Rating Scale. Acta Psychiatr Scand. 1991;84(3):294–300. doi:10.1111/j.1600-0447.1991.tb03147.x
   PubMed Web of Science ®Google Scholar
• Maher JJ, Leon P, Ryan JC. Beyond insulin resistance: innate immunity in nonalcoholic steatohepatitis. Hepatology. 2008;48(2):670–678. doi:10.1002/hep.22399
   PubMed Web of Science ®Google Scholar
• Adamowicz K, Mazur A, Mak M, Samochowiec J, Kucharska-Mazur J. Metabolic syndrome and cognitive functions in schizophrenia-implementation of dietary intervention. Front Psychiatry. 2020;11:359. doi:10.3389/fpsyt.2020.00359
   PubMed Web of Science ®Google Scholar
• Yang Y, Li X, Cui Y, et al. Reduced Gray Matter Volume in Orbitofrontal Cortex Across Schizophrenia, Major Depressive Disorder, and Bipolar Disorder: a Comparative Imaging Study. Front Neurosci. 2022;16:919272. doi:10.3389/fnins.2022.919272
   PubMed Web of Science ®Google Scholar
• Alemán-Gómez Y, Najdenovska E, Roine T, et al. Partial-volume modeling reveals reduced gray matter in specific thalamic nuclei early in the time course of psychosis and chronic schizophrenia. Hum Brain Mapp. 2020;41(14):4041–4061. doi:10.1002/hbm.25108
   PubMed Web of Science ®Google Scholar
• Rich AM, Cho YT, Tang Y, et al. Amygdala volume is reduced in early course schizophrenia. Psychiatry Res Neuroimaging. 2016;250:50–60. doi:10.1016/j.pscychresns.2016.02.006
   PubMed Web of Science ®Google Scholar
• Stice E, Yokum S, Burger KS, et al. Youth at risk for obesity show greater activation of striatal and somatosensory regions to food. J Neurosci. 2011;31:4360–4366. doi:10.1523/jneurosci.6604-10.2011
   PubMed Web of Science ®Google Scholar
• Stice E, Yokum S, Blum K, et al. Weight gain is associated with reduced striatal response to palatable food. J Neurosci. 2010;30:13105–13109. doi:10.1523/jneurosci.2105-10.2010
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhao H, Qiu S, et al. Altered functional brain networks in Prader-Willi syndrome. NMR Biomed. 2013;26:622–629. doi:10.1002/nbm.2900
   PubMed Web of Science ®Google Scholar
• Wang Y, Zeng L, Chen L, et al. The prevalence and clinical characteristics of diabetes mellitus in Chinese inpatients with chronic schizophrenia: a multicenter cross-sectional study. PeerJ. 2021;9:e12553. doi:10.7717/peerj.12553
   PubMed Web of Science ®Google Scholar
• Perry BI, McIntosh G, Weich S, Singh S, Rees K. The association between first-episode psychosis and abnormal glycaemic control: systematic review and meta-analysis. Lancet Psychiatry. 2016;3(11):1049–1058. doi:10.1016/S2215-0366(16)30262-0
   PubMed Web of Science ®Google Scholar
• Lang S, Schnabl B. Microbiota and fatty liver disease-the known, the unknown, and the future. Cell Host Microbe. 2020;28(2):233–244. doi:10.1016/j.chom.2020.07.007
   PubMed Web of Science ®Google Scholar
• Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115(5):1343–1351. doi:10.1172/JCI23621
   PubMed Web of Science ®Google Scholar
• Di Lorenzo R, Ferri P, Cameli M, Rovesti S, Piemonte C. Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting. Neuropsychiatr Dis Treat. 2019;15:183–198. doi:10.2147/NDT.S189245
   PubMed Web of Science ®Google Scholar
• Bolstad A, Andreassen OA, Røssberg JI, et al. Previous hospital admissions and disease severity predict the use of antipsychotic combination treatment in patients with schizophrenia. BMC Psychiatry. 2011;11:126. doi:10.1186/1471-244X-11-126
   PubMed Web of Science ®Google Scholar
• Civan Kahve A, Kaya H, Gül Çakıl A, et al. Multiple antipsychotics use in patients with schizophrenia: why do we use it, what are the results from patient follow-ups? Asian J Psychiatr. 2020;52:102063. doi:10.1016/j.ajp.2020.102063
   PubMed Web of Science ®Google Scholar
• May M, Barlow D, Ibrahim R, Houseknecht KL. Mechanisms underlying antipsychotic-induced NAFLD and iron dysregulation: a multi-omic approach. Biomedicines. 2022;10(6):548. doi:10.3390/biomedicines10061225
   PubMed Web of Science ®Google Scholar
• Mouzaki M, Yodoshi T, Arce-Clachar AC, et al. Psychotropic medications are associated with increased liver disease severity in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2019;69(3):339–343. doi:10.1097/MPG.0000000000002401
   PubMed Web of Science ®Google Scholar
• Centorrino F, Goren JL, Hennen J, et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry. 2004;161(4):700–706. doi:10.1176/appi.ajp.161.4.700
   PubMed Web of Science ®Google Scholar
• Gallego JA, Nielsen J, de Hert M, et al. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf. 2012;11:527–542. doi:10.1517/14740338.2012.683523
   PubMed Web of Science ®Google Scholar
• Jeon SW, Kim YK. Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: antipsychotic Polypharmacy and Metabolic Syndrome. Int J Mol Sci. 2017;18(10):2174. doi:10.3390/ijms18102174
   PubMed Web of Science ®Google Scholar
• Kelly AC, Sheitman BB, Hamer RM, et al. A naturalistic comparison of the long-term metabolic adverse effects of clozapine versus other antipsychotics for patients with psychotic illnesses. J Clin Psychopharmacol. 2014;34:441–445. doi:10.1097/JCP.0000000000000159
   PubMed Web of Science ®Google Scholar
• Silvestre JS, Prous J. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol. 2005;27:289–304. doi:10.1358/mf.2005.27.5.908643
   PubMed Web of Science ®Google Scholar
• Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318–378. doi:10.3109/15622975.2012.696143
   PubMed Web of Science ®Google Scholar
• Aarøe ASK, Odgaard Maeng K, Leifsdottir Jacobsen R, et al. Hepatic steatosis in patients with schizophrenia: a clinical cross-sectional study. Nord J Psychiatry. 2022;76(2):114–119. doi:10.1080/08039488.2021.1939779
   PubMed Web of Science ®Google Scholar
• Sun H, Liu Q, Wang X, et al. The longitudinal increments of serum alanine aminotransferase increased the incidence risk of metabolic syndrome: a large cohort population in China. Clin Chim Acta. 2019;488:242–247. doi:10.1016/j.cca.2018.10.033
   PubMed Web of Science ®Google Scholar
• Wang M, Wang M, Zhang R, et al. A combined association of serum uric acid, alanine aminotransferase and waist circumference with non-alcoholic fatty liver disease: a community-based study. PeerJ. 2022;10:e13022. doi:10.7717/peerj.13022
   PubMed Web of Science ®Google Scholar
• Sunny NE, Parks EJ, Browning JD, Burgess SC. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab. 2011;14(6):804–810. doi:10.1016/j.cmet.2011.11.004.
   PubMed Web of Science ®Google Scholar
• Sookoian S, Castaño GO, Scian R, et al. Serum aminotransferases in nonalcoholic fatty liver disease are a signature of liver metabolic perturbations at the amino acid and Krebs cycle level. Am J Clin Nutr. 2016;103(2):422–434. doi:10.3945/ajcn.115.118695
   PubMed Web of Science ®Google Scholar
• van der Vorst EPC. High-density lipoproteins and apolipoprotein A1. Subcell Biochem. 2020;94:399–420. doi:10.1007/978-3-030-41769-7_16
   PubMedGoogle Scholar
• Hussain MM, Shi J, Dreizen P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res. 2003;44(1):22–32. doi:10.1194/jlr.r200014-jlr200
   PubMed Web of Science ®Google Scholar
• Mabrouk H, Mechria H, Mechri A, et al. Paraoxonase 1 activity and lipid profile in schizophrenic patients. Asian J Psychiatr. 2014;9:36–40. doi:10.1016/j.ajp.2013.12.019
   PubMedGoogle Scholar
• Canfrán-Duque A, Casado ME, Pastor O, et al. Atypical antipsychotics alter cholesterol and fatty acid metabolism in vitro. J Lipid Res. 2013;54(2):310–324. doi:10.1194/jlr.M026948
   PubMed Web of Science ®Google Scholar
• Nass KJ, van den Berg EH, Faber KN, Schreuder TCMA, Blokzijl H, Dullaart RPF. High prevalence of apolipoprotein B dyslipoproteinemias in non-alcoholic fatty liver disease: the lifelines cohort study. Metabolism. 2017;72:37–46. doi:10.1016/j.metabol.2017.04.004
   PubMed Web of Science ®Google Scholar
• Wang J, Zhu W, Huang S, et al. Serum apoB levels independently predict the development of non-alcoholic fatty liver disease: a 7-year prospective study. Liver Int. 2017;37(8):1202–1208. doi:10.1111/liv.13363
   PubMed Web of Science ®Google Scholar
• Li M, Shu W, Zunong J, et al. Predictors of non-alcoholic fatty liver disease in children. Pediatr Res. 2022;92:322–330. doi:10.1038/s41390-021-01754-6
   PubMed Web of Science ®Google Scholar